Publication & Citation Trends
Publications
0 total
Selective Inhibition of Interleukin-2 Inducible T Cell Kinase (ITK) Enhances Anti-Tumor Immunity in Association with Th1-skewing, Cytotoxic T cell Activation, and Reduced T Cell Exhaustion OA
Cited by 2
Semantic Scholar
Abstract 1813: Selective ITK blockade induces antitumor responses and enhances efficacy to immune checkpoint inhibitors in preclinical models
Cited by 0
Semantic Scholar
Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).
Cited by 63
Semantic Scholar
Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells OA
Cited by 0
Semantic Scholar
Abstract 1313: CPI-818: A selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) that inhibits T-cell receptor signaling, promotes Th1 skewing, and achieves objective tumor responses when administered to dogs with T cell lymphomas
Cited by 1
Semantic Scholar
The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance OA
Cited by 21
Semantic Scholar
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors.
Cited by 81
Semantic Scholar
Prolonged and tunable residence time using reversible covalent kinase inhibitors OA
Cited by 371
Semantic Scholar
Research Topics
Chronic Lymphocytic Leukemia Research
(10)
Blood Coagulation and Thrombosis Mechanisms
(8)
Histone Deacetylase Inhibitors Research
(7)
Fibroblast Growth Factor Research
(7)
Protein Degradation and Inhibitors
(7)
Affiliations
University of Idaho
University of Pittsburgh
Sanofi (United States)
Epix Pharmaceuticals (United States)
Pharmacyclics (United States)